Lilly to Showcase Data from its Alzheimer's Disease Portfolio at the Alzheimer's Association International Conference

Eli Lilly and Company has announced that 23 presentations will be given at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark from 12–17 July 2014. Of particular interest are three oral presentations being highlighted by the Alzheimer's Association via a "reporter tips sheet" or a "featured research session" that may provide important insights to physicians, and increase knowledge through basic research that could inform future clinical research trials:
• Combination Therapy with a Plaque Specific Abeta Antibody and BACE Inhibitor Results in Dramatic Plaque Lowering in Aged PDAPP Transgenic Mice (Sun., July 13, 4:00 p.m. - 5:30 p.m. CEST, Auditorium 15). This study provides basic research to support the possibility of using combination therapy to achieve maximal removal of beta-amyloid pathology, a possible cause of Alzheimer's disease.
• Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease (Tues., July 15, 8:30 a.m. - 10:00 a.m. CEST, Auditorium 15). This study evaluates the relationship between cognitive and functional decline in mild Alzheimer's disease.
♦ Also to be presented during a Poster Session (P2-390), Mon., July 14, 11:45 a.m. - 2:15 p.m.CEST
• Effect of Amyloid Imaging on Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criterion (Wed., July 16, 2:15 p.m. - 3:45 p.m. CEST, Hall C5 A). This study looks at whether patients who meet the Appropriate Use Criteria (AUC) would be more likely to receive different care if they had a beta-amyloid imaging scan as part of their diagnostic work-up, compared to patients who do not meet the AUC.
Lilly will also present a poster, "Delayed-Start Analyses of Solanezumab Phase 3 EXPEDITION Studies in Mild Alzheimer's Disease," (Poster [P4-172], Wed., July 16, 11:45 a.m. - 2:15 p.m. CEST), which will compare effects among delayed-start and early-start treatment groups.
"We are pleased to have a strong scientific presence at this year's AAIC, highlighting our continued commitment to research and sharing key learnings with the Alzheimer's disease community as a whole," said Eric Siemers, MD, senior medical director of Lilly's Alzheimer's disease team. "The coming together of the scientific community at this meeting is crucial as the prevalence of the disease continues to rise with over 44 million people around the world with dementia, set to reach over 75 million by 2030."[1]
Reference
1. www.alz.co.uk/research/GlobalImpactDementia2013.pdf
Related News
-
News Closing 2024 with Editors' picks of top articles from the past year
Coming to the end of 2024 and it’s certainly been a busy year, for CPHI and for the rest of the pharmaceutical and healthcare industry. Topics of conversation throughout the last 12 months have been varied, touching on the technical, to the polit... -
News SCHOTT Pharma’s sustainable journey with CPHI
Sustainability is of paramount importance in the pharmaceutical industry. See how a recent partnership between CPHI and SCHOTT Pharma has helped to highlight and accelerate their sustainability journey to reach global goals. -
News CPHI Podcast Series: Investing in a vision for the future of life sciences
In this episode Lucy Chard is joined by Rajiv Khatau to discuss the importance of looking into new therapeutic areas and some of the more niche areas of pharmaceuticals, and investing in the future of the industry. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News CPHI Milan 2024: Excerpts from the Exhibitors
After another successful year of bringing the pharmaceutical community together at CPHI Milan in October, hear direct from the exhibitors on why the event is so important for them and the industry as a whole. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo... -
News Key Insights from the Heart of Pharma: an exclusive CPHI Online report
CPHI Milan, held from October 8–10, 2024 in the historic Fiera Milano, celebrated its 35th edition of bringing together the pharmaceutical industry and supply chain for 3 days of collaborating and innovating. Our first CPHI Wrap-Up Report brings ...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance